CJC-1295 (no DAC) + Ipamorelin

This research blend co-lyophilizes CJC-1295 (no DAC) (5 mg) with Ipamorelin (5 mg) in a single vial to study the synergistic GHRH analogue + GH secretagogue combination. CJC-1295 (no DAC) drives pulsatile GHRH-receptor activation with a short half-life mimicking physiological GH release, while Ipamorelin selectively activates the GHS-R1a receptor without significant effects on cortisol, prolactin, or aldosterone. Together they produce amplified, clean GH pulses, supporting research into pulse dynamics, IGF-1 response, and somatotropic axis modulation.